Cybin Inc SEC Filings

Cybin Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 2,514,667 common shares, representing 5.0% of the class as of 04/07/2026. The filing is a joint filing under a signed agreement dated 04/09/2026.

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 2,397,721 Common Shares (4.8%) of Cybin Inc.

The filing states these reporting persons acquired beneficial ownership in excess of 5% on 03/19/2026 but ceased to be beneficial owners of more than 5% by the date of this Schedule 13G filing. The submission includes a Joint Filing Agreement dated 03/25/2026.

Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K highlighting the appointment of Jill Conwell as Chief People Officer, effective immediately. She brings more than two decades of life sciences leadership across organizational strategy, talent development, communications, and investor relations.

Helus Pharma is a clinical stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. Its lead program HLP003 is in Phase 3 for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder.

Cybin Inc., operating as Helus Pharma, reported positive topline Phase 2 results for HLP004 in generalized anxiety disorder (GAD). In adults with moderate-to-severe GAD who remained symptomatic on standard antidepressant therapy, adjunctive 20 mg HLP004 achieved a mean 10.4-point reduction in Hamilton Anxiety Rating Scale scores at six weeks (p<0.0001), on top of standard of care.

Across the pooled study population, 67% were responders and 39% were in remission at six months. Treatment was generally well-tolerated with no drug-related serious adverse events or suicidality-related safety signals, and the acute drug effects lasted about 90 minutes with most Phase 1 participants ready for discharge within roughly three hours.

Cybin Inc. filed a Form 6-K to correct how certain previously filed documents are linked to its Canadian shelf registration in the United States. The company is now incorporating Exhibits 99.1-99.4 by reference into its Form F-10 registration statement with file number 333-292294.

These exhibits include interim consolidated financial statements and related management discussion and analysis for the three and nine months ended December 31, 2025, along with news releases dated February 10 and February 13, 2026. The filing replaces an earlier, inadvertent cross-reference to a different Form F-10 registration statement (file number 333-289139).

Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K that incorporates a news release into its Canadian F-10 shelf. The release announces that former Pfizer Executive Vice President and Chief Medical Officer Dr. Freda Lewis-Hall has joined Helus Pharma’s Board of Directors and will chair its Scientific Advisory Committee.

The company highlights her four decades of experience in psychiatry, drug development, and global medical leadership, including roles at major biopharmaceutical companies. The filing also reiterates Helus Pharma’s focus on novel serotonergic agonists, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, both aimed at serious mental health conditions.

Cybin Inc., doing business as Helus Pharma, has appointed Michael Cola as Chief Executive Officer, effective February 10, 2026. The company highlights this leadership change as it advances a pipeline of next-generation mental health therapies toward key clinical and corporate milestones.

Cola brings more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and serving as President and CEO of Avalo Therapeutics. He has also held senior roles at Astra-Merck, AstraZeneca, and served on boards of Phathom Pharmaceuticals and Sage Therapeutics.

OrbiMed Advisors LLC and OrbiMed Capital LLC report significant ownership stakes in Cybin Inc.’s common stock. OrbiMed Advisors reports beneficial ownership of 1,417,900 shares, or 2.8% of the class, while OrbiMed Capital reports 2,422,600 shares, or 4.9% of the class.

Together, the reporting persons hold 7.7% of Cybin’s common shares in the aggregate on behalf of other persons entitled to dividends or sale proceeds. The positions are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Cybin.

Cybin Inc., operating commercially as Helus Pharma, reports that Nature Medicine has published results from a Phase 2a randomized, placebo-controlled trial of SPL026 in adults with moderate-to-severe major depressive disorder. The single 21.5 mg intravenous dose met the primary endpoint, delivering statistically and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale scores at two weeks versus placebo (mean difference: -7.35). Antidepressant effects appeared within one week, were sustained to three months, and some participants improved for up to six months, with no treatment-related serious adverse events reported. Response rates at Week 2 were 35% for SPL026 versus 12% for placebo, and remission rates were 29% versus 12%. Although intravenous SPL026 is not being advanced, the data support Helus’s short-acting serotonergic agonist approach and inform its HLP004 program, with Phase 2 topline data in generalized anxiety disorder expected in Q1 2026.